PapersFlow Research Brief
Inhalation and Respiratory Drug Delivery
Research Guide
What is Inhalation and Respiratory Drug Delivery?
Inhalation and Respiratory Drug Delivery is the administration of therapeutic agents via the respiratory tract using inhaler devices, aerosols, nanoparticles, and dry powder inhalers to target lung diseases and achieve pulmonary deposition.
This field encompasses 63,816 works on pulmonary drug delivery techniques, including inhaler devices, nanoparticles, aerosol therapy, and dry powder inhalers. Key areas include respiratory tract deposition, lung diseases, nanomedicine, and inhaled insulin delivery. Research addresses particle engineering and ultrafine particle translocation in the lungs.
Topic Hierarchy
Research Sub-Topics
Dry Powder Inhalers
This sub-topic covers the formulation, particle engineering, and device design of dry powder inhalers for efficient pulmonary drug delivery. Researchers study powder flow properties, aerosolization mechanisms, and lung deposition profiles to optimize therapeutic efficacy.
Respiratory Tract Deposition
This sub-topic examines the physics of aerosol particle deposition in the upper and lower airways, including factors like particle size, inhalation flow, and airway geometry. Researchers use computational fluid dynamics and in vivo imaging to model and predict regional lung doses.
Pulmonary Nanoparticles
This sub-topic focuses on nanoparticle design for inhalation, including synthesis, stability in aerosols, and transcytosis across lung epithelia. Researchers investigate biocompatibility, mucociliary clearance evasion, and targeted delivery for local and systemic therapies.
Metered Dose Inhalers
This sub-topic addresses propellant-based metered dose inhalers, focusing on formulation with hydrofluoroalkanes, valve performance, and plume characteristics. Researchers study spray drying, actuator design, and coordination issues to enhance dose reproducibility.
Inhaled Biologics
This sub-topic explores non-invasive delivery of proteins, peptides, and nucleic acids via inhalation, including insulin and monoclonal antibodies. Researchers investigate stabilization, aggregation prevention, and immunogenicity in the pulmonary environment.
Why It Matters
Inhalation and Respiratory Drug Delivery enables targeted treatment of lung diseases such as asthma and idiopathic pulmonary fibrosis by optimizing aerosol deposition in the respiratory tract. Quanjer Ph et al. (1993) standardized lung function tests, including lung volumes and forced ventilatory flows, which underpin dosing assessments in inhaler therapies. de Jong (2008) examined nanoparticle applications and hazards, highlighting their role in drug delivery while noting potential translocation risks to the brain as shown by Oberdörster et al. (2004), who demonstrated that inhaled ultrafine particles deposit efficiently in nasal, tracheobronchial, and alveolar regions and translocate to the brain. Bateman et al. (2007) provided the GINA executive summary for asthma management, emphasizing adapted inhaler-based strategies worldwide. Raghu et al. (2015) updated guidelines recommending specific interventions for idiopathic pulmonary fibrosis, relying on precise pulmonary delivery metrics.
Reading Guide
Where to Start
"Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society." by Quanjer Ph et al. (1993), as it provides foundational standardization for assessing respiratory function essential to all inhalation delivery studies.
Key Papers Explained
Quanjer Ph et al. (1993) established lung function standardization, which Bateman et al. (2007) applied in the GINA asthma guidelines recommending inhaler therapies. de Jong (2008) built on this by exploring nanoparticle drug delivery applications and hazards, while Oberdörster et al. (2004) detailed ultrafine particle deposition and translocation risks relevant to those nanoparticles. Raghu et al. (2015) extended clinical guidelines to idiopathic pulmonary fibrosis treatments, relying on precise pulmonary metrics from prior standardization works.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers involve refining particle engineering for dry powder inhalers and nanomedicine to enhance respiratory tract deposition in lung diseases, as indicated by the 63,816 works in this cluster. Focus persists on aerosol therapy safety amid translocation concerns from Oberdörster et al. (2004) and nanoparticle hazards from de Jong (2008). No recent preprints or news available.
Papers at a Glance
Frequently Asked Questions
What are the main techniques in inhalation drug delivery?
Main techniques include inhaler devices, nanoparticles, aerosol therapy, dry powder inhalers, and particle engineering. These methods target respiratory tract deposition for treating lung diseases and delivering agents like inhaled insulin. de Jong (2008) details nanoparticle applications in drug delivery alongside associated hazards.
How do ultrafine particles behave in the respiratory system?
Inhaled ultrafine particles deposit efficiently in nasal, tracheobronchial, and alveolar regions. Oberdörster et al. (2004) showed these particles translocate to the brain, contributing to potential adverse effects from particulate matter. This impacts safety assessments in aerosol therapies.
What standardization exists for lung function in drug delivery?
Quanjer Ph et al. (1993) reported standardization of lung volumes and forced ventilatory flows by the European Respiratory Society. This official statement supports consistent evaluation of respiratory function in inhalation therapy trials. It aids in measuring drug deposition and efficacy.
What guidelines address asthma management via inhalation?
Bateman et al. (2007) outlined the GINA executive summary for global asthma strategy, recommending inhaler-based management adapted to local resources. Advances in understanding asthma improved control through pulmonary delivery. This guides inhaler device use worldwide.
What treatments are recommended for idiopathic pulmonary fibrosis?
Raghu et al. (2015) provided an ATS/ERS/JRS/ALAT guideline update favoring specific interventions for idiopathic pulmonary fibrosis. The panel rationalized recommendations based on evidence for pulmonary treatments. This informs inhalation-based therapies for interstitial lung diseases.
What role do nanoparticles play in pulmonary delivery?
Nanoparticles enable targeted drug delivery to the lungs via inhalation. de Jong (2008) reviewed their applications and hazards in nanomedicine. Oberdörster et al. (2004) confirmed translocation of inhaled ultrafine nanoparticles to extrapulmonary sites.
Open Research Questions
- ? How can nanoparticle design minimize translocation of inhaled ultrafine particles to the brain while maximizing lung-specific drug release?
- ? What particle engineering strategies optimize deposition in diseased lungs versus healthy respiratory tracts?
- ? Which inhaler device modifications improve delivery of insulin and other biologics to the deep lung?
- ? How do standardized lung function metrics predict variability in aerosol therapy outcomes across patient populations?
- ? What mechanisms control drug release from degradable polymeric nanoparticles in pulmonary environments?
Recent Trends
The field maintains 63,816 works with sustained focus on pulmonary drug delivery, inhaler devices, nanoparticles, and dry powder inhalers.
High-citation papers like Quanjer Ph et al. with 3844 citations and de Jong (2008) with 3763 citations continue to anchor research on lung function standardization and nanomedicine applications.
1993Growth data over 5 years is unavailable, and no recent preprints or news coverage reported.
Research Inhalation and Respiratory Drug Delivery with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Inhalation and Respiratory Drug Delivery with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers